Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 6
2009 5
2010 3
2011 12
2012 18
2013 20
2014 26
2015 32
2016 42
2017 57
2018 53
2019 50
2020 37
2021 32
2022 40
2023 32
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

417 results

Results by year

Filters applied: . Clear all
Page 1
The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
Afzali A, Furtner D, Melsheimer R, Molloy PJ. Afzali A, et al. Adv Ther. 2021 May;38(5):2077-2093. doi: 10.1007/s12325-021-01688-9. Epub 2021 Mar 21. Adv Ther. 2021. PMID: 33745111 Free PMC article. Review.
Third, an interchangeability designation from the US Food and Drug Administration only permits a biosimilar to be automatically substituted for its innovator, not other biosimilars (if available). ...However, the supply chains of innovators and biosimilars …
Third, an interchangeability designation from the US Food and Drug Administration only permits a biosimilar to be automaticall …
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective.
Joshi SR, Mittra S, Raj P, Suvarna VR, Athalye SN. Joshi SR, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):693-704. doi: 10.1080/14712598.2022.2112664. Epub 2022 Aug 21. Expert Opin Biol Ther. 2023. PMID: 35993301
'Interchangeability' status, a regulatory designation by the US FDA, bestowed to some biosimilars, enables confidence in high-quality, bio-equivalent biosimilar of insulin with key global approvals. ...Biocon-Viatris's biosimilar Insulin Glargine (Semg …
'Interchangeability' status, a regulatory designation by the US FDA, bestowed to some biosimilars, enables confidence in high- …
Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology.
Soares JCS, Cavalcanti IDL, Vasconcelos JLA. Soares JCS, et al. J Oncol Pharm Pract. 2021 Sep;27(6):1491-1502. doi: 10.1177/10781552211016099. Epub 2021 May 14. J Oncol Pharm Pract. 2021. PMID: 33990164 Review.
OBJECTIVE: To evaluate the safety in the interchangeability of biosimilar products approved for cancer treatment from a pharmaceutical perspective. METHODS: A literature review was carried out using the descriptors "Biosimilar", "Oncology Therapy", "Interc …
OBJECTIVE: To evaluate the safety in the interchangeability of biosimilar products approved for cancer treatment from a pharma …
Biosimilars and the era of interchangeability.
The Lancet Rheumatology. The Lancet Rheumatology. Lancet Rheumatol. 2023 Sep;5(9):e495. doi: 10.1016/S2665-9913(23)00213-8. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251490 No abstract available.
Biosimilars for the treatment of psoriasis.
Puig L, López-Ferrer A. Puig L, et al. Expert Opin Biol Ther. 2019 Oct;19(10):993-1000. doi: 10.1080/14712598.2019.1636963. Epub 2019 Jul 1. Expert Opin Biol Ther. 2019. PMID: 31237786 Review.
We have also reviewed clinical trials of biosimilars approved for the treatment of psoriasis. Expert opinion: Because of efficacy and convenience of administration, adalimumab biosimilars will be used to greater extent than etanercept or infliximab to treat patients …
We have also reviewed clinical trials of biosimilars approved for the treatment of psoriasis. Expert opinion: Because of efficacy and …
Biosimilars in supportive care.
Foreman E. Foreman E. Curr Opin Oncol. 2020 Jul;32(4):282-288. doi: 10.1097/CCO.0000000000000631. Curr Opin Oncol. 2020. PMID: 32541314 Review.
PURPOSE OF REVIEW: This review covers recent publications relating to the use of biosimilar medicines in the supportive care of cancer patients, and broader publications focussed on the benefits and challenges of implementing biosimilars into clinical practice. ...N …
PURPOSE OF REVIEW: This review covers recent publications relating to the use of biosimilar medicines in the supportive care of cance …
Biosimilars in rheumatology.
Araújo FC, Gonçalves J, Fonseca JE. Araújo FC, et al. Pharmacol Res. 2019 Nov;149:104467. doi: 10.1016/j.phrs.2019.104467. Epub 2019 Sep 27. Pharmacol Res. 2019. PMID: 31568820 Review.
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab and rituximab biosimilars. In Europe, North America and some countries of Asia, development is strictly regulated and only those prese …
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab a …
Biosimilars Have Arrived: Rituximab.
Greenwald M, Tesser J, Sewell KL. Greenwald M, et al. Arthritis. 2018 Mar 22;2018:3762864. doi: 10.1155/2018/3762864. eCollection 2018. Arthritis. 2018. PMID: 29765782 Free PMC article. Review.
An understanding of the process of the interchangeable designation of a biosimilar is important in the context of patient outcomes. We conducted an analysis of the properties and benefits of rituximab in the treatment of inflammatory diseases, the development and ap …
An understanding of the process of the interchangeable designation of a biosimilar is important in the context of patient outc …
Biosimilars: The US Regulatory Framework.
Christl LA, Woodcock J, Kozlowski S. Christl LA, et al. Annu Rev Med. 2017 Jan 14;68:243-254. doi: 10.1146/annurev-med-051215-031022. Epub 2016 Oct 28. Annu Rev Med. 2017. PMID: 27813877 Review.
With the passage of the Biologics Price Competition and Innovation Act of 2009, the US Food and Drug Administration established an abbreviated pathway for developing and licensing biosimilar and interchangeable biological products. The regulatory framework and the t …
With the passage of the Biologics Price Competition and Innovation Act of 2009, the US Food and Drug Administration established an abbreviat …
417 results